Autologous immune enhancement therapy: A case report of a stage IV colonic cancer

Subramani,Baskar; Ratnavelu,Kananathan; Pullai,Chithra  Ramanathan; Krishnan,Kohila; Sugadan,Sheela  Devi; Deng,Xuewen; Hiroshi,Terunuma

doi:10.3892/ol.2013.1246

Autologous immune enhancement therapy: A case report of a stage IV colonic cancer

Authors:
- Baskar Subramani
- Kananathan Ratnavelu
- Chithra Ramanathan Pullai
- Kohila Krishnan
- Sheela Devi Sugadan
- Xuewen Deng
- Terunuma Hiroshi
View Affiliations

Affiliations: Nichi-Asia Life Sciences Sdn. Bhd., Petaling Jaya 47810, Malaysia, Nilai Cancer Institute (NCI) Hospital, Nilai 71800, Malaysia, Biotherapy Institute of Japan, Tokyo 135-0051, Japan
Published online on: March 12, 2013 https://doi.org/10.3892/ol.2013.1246
Pages: 1611-1614

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Current modalities of cancer treatment, including surgery, chemotherapy and radiotherapy, show marginal therapeutic responses in cancer patients. In adoptive immunotherapy, interleukin-2 (IL-2) activated immune cells demonstrated notable results in patients with advanced malignant disease. The present study reports the efficacy and safety of repetitive infusions of autologous immune enhancement therapy (AIET) in a stage IV colonic cancer patient who had already received first-line chemotherapeutic drugs. Peripheral blood was aspirated from the patient. Specifically, natural killer (NK) cells and T-lymphocytes were isolated from the peripheral blood mononuclear cells (PBMCs). These cells were activated and expanded ex vivo for 14 days and were transfused intravenously to the patient. After six infusions of AIET, the carcinoembryonic antigen (CEA) level was decreased from 901 to 437 U/ml, regression of lesions was noted and there were no adverse reactions during the course of this therapy. Thus, AIET may be a promising anticancer approach to eradicate tumor cells with other conventional therapies.

View Figures

View References

1	Gill S, Thomas RR and Goldberg RM: Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther. 18:683–692. 2003. View Article : Google Scholar
2	Kalady MF, Dejulius KL, Sanchez JA, et al: BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 55:128–133. 2012. View Article : Google Scholar : PubMed/NCBI
3	Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30. 2004. View Article : Google Scholar
4	Medinger M, Steinbild S and Mross K: Adjuvant and palliative anticancer treatment of colon carcinoma in 2004. Praxis (Bern 1994). 93:1633–1644. 2004.(In German).
5	Köhne CH: Palliative therapy of colorectal cancer. Onkologie. 26(Suppl 7): 41–47. 2003.(In German).
6	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
7	Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
8	Goto S, Shirotani N, Hatakeyama M, et al: Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion). Anticancer Res. 22:2461–2464. 2002.PubMed/NCBI
9	Gattinoni L, Powell DJ, Rosenberg SA and Restifo NP: Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 6:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
10	zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C and Bernhard H: Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62:2244–2247. 2002.
11	Terunuma H, Deng X, Dewan Z, Fujimoto S and Yamamoto N: Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 27:93–110. 2008. View Article : Google Scholar : PubMed/NCBI
12	Smyth MJ, Hayakawa Y, Takeda K and Yagita H: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2:850–861. 2002. View Article : Google Scholar : PubMed/NCBI
13	Hsu KC and Dupont B: Natural killer cell receptors: regulating innate immune responses to hematologic malignancy. Semin Hematol. 42:91–103. 2005. View Article : Google Scholar : PubMed/NCBI
14	Kiessling R, Klein E and Wigzell H: ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells Specificity and distribution according to genotype. Eur J Immunol. 5:112–117. 1975.
15	Kärre K, Ljunggren HG, Piontek G and Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 319:675–678. 1986.
16	Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2097–2100. 2002. View Article : Google Scholar
17	Takada M, Terunuma H, Deng X, et al: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI
18	Cui Z, Willingham MC, Hicks AM, et al: Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA. 100:6682–6687. 2003. View Article : Google Scholar : PubMed/NCBI
19	Hicks AM, Riedlinger G, Willingham MC, et al: Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA. 103:7753–7758. 2006. View Article : Google Scholar : PubMed/NCBI
20	Gumperz JE and Parham P: The enigma of the natural killer cell. Nature. 378:245–248. 1995. View Article : Google Scholar : PubMed/NCBI
21	Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F and Escudier B: Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. J Biol Response Mod. 9:546–555. 1990.PubMed/NCBI
22	Rabinowich H, Sedlmayr P, Herberman RB and Whiteside TL: Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol. 135:454–470. 1991. View Article : Google Scholar
23	Harada H, Saijo K, Watanabe S, Tsuboi K, Nose T, Ishiwata I and Ohno T: Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res. 93:313–319. 2002. View Article : Google Scholar : PubMed/NCBI
24	Coca S, Perez-Piqueras J, Martinez D, et al: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 79:2320–2328. 1997. View Article : Google Scholar : PubMed/NCBI
25	Stinchcombe JC and Griffiths GM: Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol. 23:495–517. 2007. View Article : Google Scholar : PubMed/NCBI
26	DiLillo DJ, Yanaba K and Tedder TF: B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 184:4006–4016. 2010.
27	Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58:3491–3494. 1998.
28	Yu P and Fu YX: Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 86:231–245. 2006. View Article : Google Scholar : PubMed/NCBI
29	Todaro M, D’Asaro M, Caccamo N, et al: Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol. 182:7287–7296. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ogino S, Nosho K, Irahara N, et al: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 15:6412–6420. 2009. View Article : Google Scholar
31	Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
32	Pagès F, Kirilovsky A, Mlecnik B, et al: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 27:5944–5951. 2009.PubMed/NCBI
33	Sun JC and Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:339–342. 2003. View Article : Google Scholar : PubMed/NCBI
34	Fehniger TA, Bluman EM, Porter MM, et al: Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 106:117–124. 2000. View Article : Google Scholar : PubMed/NCBI
35	Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 7:1863–1874. 1989.PubMed/NCBI
36	Atzpodien J, Kirchner H, Hänninen EL, Deckert M, Fenner M and Poliwoda H: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer. 29A(Suppl 5): S6–S8. 1993. View Article : Google Scholar : PubMed/NCBI